Staurosporine

目录号:S1421 别名: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 2186.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献10篇:

客户使用该产品的4个实验数据:

  • Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

    Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

    Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。
靶点
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外研究

Staurosporine 也强抑制HeLa S3细胞,IC50为4 nM。[1]Staurosporine 也抑制多种其他蛋白激酶,包括PKA, PKG, 磷酸激酶, S6 激酶, 肌球蛋白轻链激酶(MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, 和Syk , IC50分别为 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, 和 16 nM。[3] Staurosporine (1 μM) 诱导 PC12细胞90%以上凋亡,这种作用可被过量表达的Bcl-2抑制,或者zVAD-fmk, cycloheximide (10 μM) 及actinomycin D (5 μM)处理也可抑制。相应地, Staurosporine处理,诱导细胞内游离钙水平 [Ca2+]i快速且持久的提升,线粒体活性氧(ROS)的积累,及 随后的线粒体功能障碍。[4]通过caspase-8激活和Bid 分裂,功能性caspase-3的表达可增强Staurosporine诱导MCF7细胞死亡。[5] 1 μM Staurosporine处理,只部分抑制IL-3刺激的Bcl2 磷酸化,而完全阻断PKC调节的 Bcl2磷酸化。[6] Staurosporine 诱导人类包皮成纤维细胞AG-1518凋亡,根据溶酶体组织蛋白酶D调节的 细胞色素 c释放和 caspase 激活。[7] 除了激活传统线粒体凋亡通路, Staurosporine触发一种新型内在凋亡通路, 依赖Apaf-1存在时对caspase-9的激活。[8]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells NEnqe4REgXSxdH;4bYPDqGG|c3H5 NXu1R41oPDhiaB?= MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NHWtNFYh|ryPLh?= MmXrNlE{QDhzOUG=
human colon cancer cell line (LoVo cells) M{S3bXBzd2yrZnXyZZRqd25iYYPzZZk> NWr6NndkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubDDsbY5mKCiOb2\vJINmdGy|KTD1d4lv\yCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txONg>? M3fJeFEyPTlzNUC1
human LoVo cells M4CzU3Bzd2yrZnXyZZRqd25iYYPzZZk> NEn3S5M1QCC2bzC3NkBp M3TwXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6 M17yOVIzOTh{OUK5
P19 cells MXHGeY5kfGmxbjDhd5NigQ>? NYf3OpZxUW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTBwMECyJO69VS5? M3nBZ|E2PzdzNEG5
human BJ cells NFPKO4REgXSxdH;4bYPDqGG|c3H5 M4\OXVczKGh? NUG4NIR2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MD6wNFIh|ryPLh?= NXv5e|RNOjJ7MkGwPFE>
human HT-29 cells NH7YOFhHfW6ldHnvckBie3OjeR?= M{K1[|IhcA>? MX7F[oZm[3Rib36gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyb4TlcpRq[WxiaX6gbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiMjDodpMhfXOrbnegTmMuOSC|dHHpcolv\yCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYm= NH\jWFAzOTR{OEO3OS=>
human A549 cells NGLE[YZEgXSxdH;4bYPDqGG|c3H5 Mk\XO|IhcA>? NXO3dGxnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3S= M3zIW|E5PDh2N{e1
human HT-29 cells Mnr6SpVv[3Srb36gZZN{[Xl? M3zjUWlvcGmkaYTpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwhcW5iaIXtZY4hUFRvMkmgZ4VtdHNidYPpcochUkNzIHT5[UB{fGGrbnnu[{BjgSCobIXvdoV{[2WwY3WgdIxifGVicnXh[IVzKGG|c3H5MEBKSzVyPUKuOUBvVQ>? M2DRUlIyPTF|Mkmz
human HT-29 cells MV3GeY5kfGmxbjDhd5NigQ>? NHTlTGEzKGh? NFzvNlVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W|c3XkJJJm\HWldHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBi\nSncjCyJIhzeyCkeTD1d4lv\yCMQ{Ggd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHPlcIwu[mG|ZXSgZZN{[XluIFXDOVA:Oi54IH7NMi=> NHO5PZMzOTl5M{GwNS=>
Sf9 cells M4K0W2Z2dmO2aX;uJIF{e2G7 NIDJV2pKdmirYnn0bY9vKG:oIHj1cYFvKFO7azDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{NCCLQ{WwQVMhdk1w MkDzNVg5OjN5OES=
human HUVEC MkSwVJJwdGmoZYLheIlwdiCjc4PhfS=> MlXDOFghfG9iN{KgbC=> NF\zPYpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVEKGGodHXyJFQ5KHSxIEeyJIhzeyCkeTDNWHQh[XO|YYm= M2TwNlIzOTh{OUK5
P19 cells NXvvUIZoTnWwY4Tpc44h[XO|YYm= NUC4TGdEUW6qaXLpeIlwdiCxZjDQdo91\WmwIFvpcoF{\SCDIHnuJHAyQSClZXzsd{whUUN3ME20JI5ONg>? NI\ydZMyPTd5MUSxPS=>
Sf9 cells NV\m[3BWTnWwY4Tpc44h[XO|YYm= M3XmUmlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBucW5iYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSS M1L1TFE4OzF3OEWz
Sf21 cells MUDGeY5kfGmxbjDhd5NigQ>? M4Pl[2lvcGmkaYTpc44hd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczygTWM2OD14IH7NMi=> M2TRU|E4ODh6MEW5
human colon carcinoma cell line HCT116 MYjGeY5kfGmxbjDhd5NigQ>? NETkV5ZEd26lZX70doF1cW:wIILldZVqemWmIH\vdkBoem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBkd2yxbjDjZZJkcW6xbXGgZ4VtdCCuaX7lJGhEXDFzNjygTWM2OD14IH7NMi=> MnH3NVU2Ozd|NEW=
human ST486 cells M3\mSHBzd2yrZnXyZZRqd25iYYPzZZk> MX[0PEB1dyB5MjDo MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOWNEi2JINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{BvVS5? MlLtNlIyQDJ7Mkm=
human MDA-MB-231 cells M3zzXGN6fG:2b4jpZ:Kh[XO|YYm= NVT2VFd2PzJiaB?= NVLTT5NTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2RuIFfJOVA:Py5zIH7NMi=> NW\L[YV{OTh2OES3O|U>
P19 cells M4m1Z2Z2dmO2aX;uJIF{e2G7 MlHvTY5pcWKrdHnvckBw\iCFeXPsbY4u\GWyZX7k[Y51KGurbnHz[UAyKGmwIGCxPUBk\WyuczygTWM2OD16IH7NMi=> NVHZfmVPOTV5N{G0NVk>
human DLD1 cells NEHNOIlRem:uaX\ldoF1cW:wIHHzd4F6 M4q1fVQ5NTd{IHi= M1TjTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRFzENUBk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVkhdk1w M4rieVIzOTh{OUK5
insect cells NH;jRoZHfW6ldHnvckBie3OjeR?= M1nyOWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUHntNUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIJ6KEiWUl[sJGlEPTB;MUCgcm0v M1XHflE6OTd7MEe2
V79 MZ cells Mnj2SpVv[3Srb36gZZN{[Xl? MnXSTY5pcWKrdHnvckBw\iCqdX3hckBidGSxc4Tldo9v\SC|eX70bIF{\SCneIDy[ZN{\WRiaX6gWlc6KE2cIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[Wymb4P0[ZJwdmVic4nueIhme2m|LDDJR|UxRTFzIH7NMi=> MX:yOFQzOjVzOR?=
P19 cells MmmySpVv[3Srb36gZZN{[Xl? MX7Jcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> NGjUVWUyPTd5MUSxPS=>
Sf9 cells NUHyXot4TnWwY4Tpc44h[XO|YYm= NH\lUlEzOCCvaX7z MUnJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEKwJI1qdnNiYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSSLDDJR|UxRTF3IH7NMi=> MkLSNVc{OTV6NUO=
human PBMC M3T1eGZ2dmO2aX;uJIF{e2G7 MVKyOEBp MomyV5VxeHKnc4Ppc44hd2ZiSVyyJJBzd2S3Y4Tpc44hcW5iaIXtZY4hWEKPQzDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUC9NVYhdk1w NVjYUHlJOTh3OEWwOFY>
human A549 cells NILEVmpEgXSxdH;4bYPDqGG|c3H5 MXW0PEBp M4jOb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9NlAhdk1w NFu4c2UzPTh{NUmzOC=>
human CEM cells M1fqNmN6fG:2b4jpZ:Kh[XO|YYm= NVy2[nd2PzJiaB?= NILvemhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v MoOyNlI6OjFyOEG=
human HeLa cells M2nCNGN6fG:2b4jpZ:Kh[XO|YYm= MYO0PEBp MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkWgcm0v NFzUOXAzPTh{NUmzOC=>
human PC3 cells NYTBdW5KS3m2b4TvfIlkyqCjc4PhfS=> MoTDOFghcA>? NVv1T3d4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkhNCCLQ{WwQVMyKG6PLh?= NXnKenBwOjV6MkW5N|Q>
human SF268 cells MWLDfZRwfG:6aXRCpIF{e2G7 NEexZnE1QCCq M4\VN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNHOjZ6IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9OFQhdk1w Mn\zNlE2OTN{OUS=
human MCF7 cells NVX6SIk6S3m2b4TvfIlkyqCjc4PhfS=> NUnUNWExPDhiaB?= NEXYPFNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVAhdk1w M322Z|IyOzh6MUmx
HEK293 cells M1PNdmN6fG:2b4jpZ:Kh[XO|YYm= M3;PXlczKGh? MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmekeubzDhd5NigSxiSVO1NF02PiCwTT6= MXqyOFc3OzJ4Mh?=
HUE cells MlnISpVv[3Srb36gZZN{[Xl? M3jwbFkxKG2rboO= NIOxSmpKdmirYnn0bY9vKG:oIG\FS2ZTOiCrbjDIWWUh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC2cnXheIVlKG[xcjC5NEBucW6|IHLl[o9z\SCYRVfGJINp[WyuZX7n[UBjgSCHTFnTRUwhUUN3ME23NEBvVS5? NGLYR|czODF5MEG2Ny=>
human A431 cells NYrGUm13S3m2b4TvfIlkyqCjc4PhfS=> MljvNlQhKGh? MmHpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{Bi\nSncjCyOEBpenNidYPpcochSW6wZYjpckBX\U[LVFOvdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDifUBOXFRiYYPzZZktKEmFNUC9O|Ahdk1w M1X0VVIzPTRzMEWx
human Jurkat cells M2DVZ3Bzd2yrZnXyZZRqd25iYYPzZZk> NGTON5JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGpCUzNiZYjwdoV{e2mwZzDJUFIue3SrbYXsZZRm\CCqdX3hckBLfXKtYYSgZ4VtdHNuIFnDOVA:PzFibl2u MYCxPVQzPzJyMx?=
HEK293 cells MX\GeY5kfGmxbjDhd5NigQ>? NVzLRmhTUW6qaXLpeIlwdiCxZjDJUE05KHKnbHXhd4Uh[nliSFXLNlk{KGOnbHzzJIV5eHKnc4PpcochWEuFLXLleIEzNCCLQ{WwQVc4KG6PLh?= NGqzPGcyPTd5MUSxPS=>
human KE-97 cells NIjWSWNEgXSxdH;4bYPDqGG|c3H5 M1OxPVczKGh? NH3X[JNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMTS17NzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|IN88UU4> NFHvN4QzPDN{OEK4Ny=>
human CHOK1 cells NI\tN|REgXSxdH;4bYPDqGG|c3H5 NV;3O2VrPDhiaB?= NFjRVnNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEUE:NMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5zMzFOwG0v M4LOeFIyPTF|Mkm0
mouse NIH/3T3 cells MlXBR5l1d3SxeHnjxsBie3OjeR?= MYq5OkBp M{Tu[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJG5KUC9|VEOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> NGKxW2EzPDN4MUWyNS=>
human A2780 cells MUPDfZRwfG:6aXRCpIF{e2G7 NH7HWmY6PiCq M13zfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= M2fHcFI1OzZzNUKx
human 8505C cells NIfrRVlEgXSxdH;4bYPDqGG|c3H5 MYe5OkBp Mom3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NInsbogzPDN4MUWyNS=>
human 518A2 cells Ml;IR5l1d3SxeHnjxsBie3OjeR?= MXq5OkBp M3H1VmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=> NXzhS2RnOjR|NkG1NlE>
human HuH7 cells NV;5ZXJqS3m2b4TvfIlkyqCjc4PhfS=> NWflbHB7PzJiaB?= M1T1UmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh2UDdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOyEQvF2u MoX2NlQ{Ojh{OEO=
FL5.12-Akt1 cells M1\H[nBzd2yrZnXyZZRqd25iYYPzZZk> NEnUSGtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZNPS5zMj3Bb5QyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjJ7IN88UU4> MWqxOlQxOzZ{Nh?=
human MiaPaCa-2 cells MXzQdo9tcW[ncnH0bY9vKGG|c3H5 MofnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPaXHQZWNiNTJiY3XscJMtKEmFNUC9NE4{PyEQvF2u MmqwNVY1OTN5OEC=
human BGC823 cells MXLDfZRwfG:6aXRCpIF{e2G7 M4r4dlczKGh? MnqyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmdEQDJ|IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzhizszNMi=> NV71dVl{OjR|MkiyPFM>
human MCF7 cells M3LBOmN6fG:2b4jpZ:Kh[XO|YYm= MYS5OkBp NV\obIFrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPCEQvF2u M4rFOlI1OzZzNUKx
human A549 cells M2W1VmN6fG:2b4jpZ:Kh[XO|YYm= MWW5OkBp NX7Hd5RsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u NVHkVldrOjR|NkG1NlE>
HEK293 cells MoTjR5l1d3SxeHnjxsBie3OjeR?= Mn;vR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|LDDFR|UxRTJizszNMi=> NXzDOlRmOjV|MU[zNVc>
human Raji cells  Mlr1R5l1d3SxeHnjxsBie3OjeR?= NHLHfnFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{NCCHQ{WwQVIh|ryPLh?= M4faWFI2OzF4M{G3
human HepG2 cells M3zaRWN6fG:2b4jpZ:Kh[XO|YYm= MlHPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEWFNUC9NkDPxE1w MVKyOVMyPjNzNx?=
human BJ cells MmLaR5l1d3SxeHnjxsBie3OjeR?= MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczygSWM2OD1{IN88UU4> MlPUNlU{OTZ|MUe=
human U937 cells NFLUeFlEgXSxdH;4bYPDqGG|c3H5 M3v5XmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w NWrWOm11OTdyOEiwOlc>

... Click to View More Cell Line Experimental Data

体内研究 在局部贫血前,使用Staurosporine(0.1-10 ng)预处理局部贫血沙鼠和大鼠模型,可防止神经元损伤,这种作用存在剂量依赖性,说明CAl锥体细胞死亡涉及PKC。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
细胞实验:[4]
+ 展开
  • Cell lines: PC12
  • Concentrations: 溶于DMSO,终浓度为1 μM
  • Incubation Time: ~32 小时
  • Method: 使用Staurosporine处理细胞32小时。细胞在4%多聚甲醛中混合,然后使用DNA结合染料Hoechst 33342染色。在荧光照明下观察细胞,测定凋亡细胞百分数。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 短暂局部贫血的雄性Mongolian沙鼠或雄性 Wistar大鼠
  • Formulation: 溶于DMSO,然后在盐水中稀释
  • Dosages: ~10 ng
  • Administration: 定向处理到海马双边CA1子域
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 466.53
化学式

C28H26N4O3

CAS号 62996-74-1
稳定性 powder
in solvent
别名 CGP 41251

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PKC Signaling Pathway Map

相关PKC产品

Tags: 购买Staurosporine | Staurosporine供应商 | 采购Staurosporine | Staurosporine价格 | Staurosporine生产 | 订购Staurosporine | Staurosporine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID